Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorhexidine mouthwash effects on esophageal microbiome
NCT02513784Completed
- Sponsor
- Columbia University
- Start
- Aug 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of chlorhexidine in reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Columbia University. Primary endpoints: Reduction of Fusobacterium Nucleatum in Saliva at 21 days and Difference in Esophageal Fusobacterium Nucleatum Between Experimental Group and No Intervention Group at 21 days. Started Aug 2015; status: completed.
02
Drugs
chlorhexidine
03
Conditions
reflux esophagitisBarrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02513784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513784.